The Virology segment was Bristol-Myers Squibb’s (BMY) second-largest revenue contributor in 2016. The segment contributed ~24.4% of BMY’s total revenue in the year. It’s made up of drugs for chronic virus diseases and infections such as hepatitis B, hepatitis C, and HIV.
Overall, the segment’s revenue fell ~10.5% to $4.7 billion in 2016, compared to $5.3 billion in 2015.
Receive e-mail alerts for new research on BMY:
Interested in BMY?
Don’t miss the next report.
Daklinza and Sunvepra, two drugs launched post-August 2014, contributed over 33% of the Virology segment’s total revenue in 2016. The revenues of these drugs fell ~2% to a total of $1.58 billion in 2016, compared to $1.60 billion in 2015. The fall followed lower sales in international markets.
The segment’s HIV franchise includes two drugs, Reyataz and Sustiva. In 2016, Sustiva’s revenue fell ~15% to $1.1 billion due to a loss of exclusivity, while Reyataz’s revenue fell 20% to $912 million compared to 2015.
Baraclude, an oral antiviral, reported a fall of ~9% to $1.2 billion in 2016, compared to $1.3 billion in 2015, due to the generic competition of entecavir tablets from Teva Pharmaceuticals (TEVA).
To divest risk, investors can consider ETFs such as the Fidelity MSCI Healthcare ETF (FHLC), which holds 3.1% of its total assets in Bristol-Myers Squibb.